Stockscreener 앱 받기
46.07
6.87%
-3.40
시간 외 거래:
47.00
0.93
+2.02%
전일 마감가:
$49.47
열려 있는:
$49.14
하루 거래량:
1.01M
Relative Volume:
0.70
시가총액:
$1.95B
수익:
-
순이익/손실:
$-63.78M
주가수익비율:
-17.19
EPS:
-2.68
순현금흐름:
$-53.91M
1주 성능:
-8.79%
1개월 성능:
-17.63%
6개월 성능:
+432.60%
1년 성능:
+217.72%
1일 변동 폭
$45.85
$49.98
1주일 범위
$45.85
$50.63
52주 변동 폭
$7.575
$63.06
Celcuity Inc Stock (CELC) Company Profile
명칭
Celcuity Inc
전화
763-392-0767
주소
16305 36TH AVENUE N, MINNEAPOLIS, MN
CELC을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CELC
Celcuity Inc
|
46.07 | 2.10B | 0 | -63.78M | -53.91M | -2.68 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.79 | 106.37B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.46 | 59.90B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.63 | 60.40B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
796.92 | 49.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.10 | 36.88B | 4.56B | -176.77M | 225.30M | -1.7177 |
Celcuity Inc Stock (CELC) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-09-22 | 개시 | Guggenheim | Buy |
| 2025-07-01 | 재개 | Stifel | Buy |
| 2024-07-22 | 개시 | Leerink Partners | Outperform |
| 2024-02-22 | 개시 | Stifel | Buy |
| 2023-12-08 | 개시 | H.C. Wainwright | Buy |
| 2021-10-08 | 개시 | Canaccord Genuity | Buy |
| 2021-09-07 | 개시 | Jefferies | Buy |
| 2021-07-29 | 개시 | Cowen | Outperform |
| 2021-07-27 | 개시 | Needham | Buy |
| 2021-01-28 | 재확인 | H.C. Wainwright | Buy |
| 2020-12-24 | 재확인 | H.C. Wainwright | Buy |
| 2020-05-11 | 재개 | Craig Hallum | Buy |
| 2018-11-20 | 개시 | H.C. Wainwright | Buy |
모두보기
Celcuity Inc 주식(CELC)의 최신 뉴스
Historical volatility pattern of Celcuity Inc. visualizedJuly 2025 PostEarnings & Weekly Market Pulse Alerts - newser.com
Celcuity's (CELC) Sell (D-) Rating Reaffirmed at Weiss Ratings - MarketBeat
Celcuity: Blink And You Missed It (NASDAQ:CELC) - Seeking Alpha
Celcuity's VIKTORIA-1 Results To Anchor ESMO Presentation; NDA Submission Underway - RTTNews
Short interest data insights for Celcuity Inc.Quarterly Investment Review & Weekly Watchlist of Top Performers - newser.com
What data driven models say about Celcuity Inc.’s futureTrade Exit Report & Safe Capital Growth Tips - newser.com
Multi asset correlation models including Celcuity Inc.Weekly Loss Report & Weekly Sector Rotation Insights - newser.com
Celcuity Inc. stock trend forecastStop Loss & Daily Stock Trend Reports - newser.com
Long term hold vs stop loss in Celcuity Inc.Layoff News & Daily Growth Stock Investment Tips - newser.com
Can technical indicators confirm Celcuity Inc.’s reversal2025 Trade Ideas & Daily Oversold Stock Bounce Ideas - newser.com
Should FDA Real-Time Review of Gedatolisib Prompt a Closer Look From Celcuity (CELC) Investors? - simplywall.st
Needham Maintains Celcuity(CELC.US) With Buy Rating, Maintains Target Price $70 - 富途牛牛
Celcuity (NASDAQ:CELC) Given Buy Rating at Needham & Company LLC - MarketBeat
How to interpret RSI for Celcuity Inc. stock2025 Institutional Moves & Daily Stock Momentum Reports - newser.com
Celcuity (CELC): Valuing the Stock After FDA Acceptance of Gedatolisib and Major Pipeline Progress - Sahm
Celcuity Expands Credit Facility to $500 Million - MSN
Why Celcuity Inc. stock appeals to dividend seekers2025 Technical Overview & Smart Investment Allocation Insights - newser.com
3 Growth Companies With High Insider Ownership Seeing Up To 63% Revenue Growth - simplywall.st
Celcuity Inc. (CELC)’s FDA NDA for Gedatolisib Accepted Under RTOR, Accelerating Review - Insider Monkey
Certain Options of Celcuity Inc. are subject to a Lock-Up Agreement Ending on 29-SEP-2025. - MarketScreener
Certain Pre-Funded Warrants of Celcuity Inc. are subject to a Lock-Up Agreement Ending on 29-SEP-2025. - MarketScreener
Certain Common Stock of Celcuity Inc. are subject to a Lock-Up Agreement Ending on 29-SEP-2025. - MarketScreener
Craig-Hallum Remains a Buy on Celcuity (CELC) - The Globe and Mail
The Bull Case For Celcuity (CELC) Could Change Following Expanded Credit Facility and Rising Commercial Ambitions - simplywall.st
Celcuity (NASDAQ:CELC) Shares Down 5.5%Time to Sell? - MarketBeat
Celcuity to present phase 3 breast cancer trial data at ESMO congress - Investing.com Nigeria
Goldman Sachs Group Inc. Sells 28,686 Shares of Celcuity, Inc. $CELC - MarketBeat
Guggenheim initiates Celcuity stock with Buy rating on breast cancer drug potential By Investing.com - Investing.com South Africa
Guggenheim initiates Celcuity stock with Buy rating on breast cancer drug potential - Investing.com Australia
Guggenheim Maintains Celcuity(CELC.US) With Buy Rating, Raises Target Price to $110 - 富途牛牛
Celcuity Inc (CELC) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Celcuity Inc 주식 (CELC) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Dalvey David | Director |
Jul 28 '25 |
Sale |
43.98 |
100,000 |
4,397,603 |
125,000 |
| Dalvey David | Director |
Jul 28 '25 |
Sale |
45.12 |
9,325 |
420,767 |
0 |
5.74%
자본화:
|
볼륨(24시간):